Member Info for steve124

Arm?

Geeforce - i'm 99% sure you are correct but I had the same faith in Dr Cave and look where that got me. Incidentally, the shareholders voted TB out there but he ended up having the last laugh.

Thanks all for your comments.

Existing Shareholders who hold shares in the Company and are on the register of members as at the close of business on 21 February 2024, will be given a priority right to participate in the Broker Option

So as this paragraph from the RNS is not true, surely we should have some redress from a regulator?

The problem of having so many eggs in one basket is when it drops from 5p to 1.5p and you don't know the reasons why (we all correctly guessed) but they had inside information and if the trials had gone badly and they were selling before the bad news hit it can cause you to worry (in this case unduly I think) but previously I'd lost £40k in NNN and am down £50k in this now due to one persons greed.

Existing Shareholders who hold shares in the Company and are on the register of members as at the close of business on 21 February 2024, will be given a priority right to participate in the Broker Option and all orders from such Existing Shareholders will be accepted and processed by Peterhouse, subject to scale-back in the event of over-subscription under the Broker Option.

Can I just clarify if any PIs got offered any of the new shares ( I own 1% of the company and I was never contacted to see if I'd like any)?

Just checked the trades today and there was a sea of red which doesn't look good.

Tried some dummy buy/sells on HL and the buy is under the mid so a lot of these are actually buys so don't believe you 1st instincts when you first see something.

“The discovery that GaM has anticancer activity against glioblastoma in pre-clinical studies is extremely exciting; it opens the door for developing it as a drug for treatment of glioblastoma in patients,” says Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology at MCW. “The anticancer mechanism of GaM applies to other solid tumors as well,” he adds.

Jennifer Connelly, MD, Associate Professor of Neurology at MCW, is Principal Investigator (PI) of the clinical trial with Dr. Chitambar serving as co-PI and Chair. Both are long-standing collaborators with Kathleen Schmainda, PhD, a co-founder of Imaging Biometrics, LLC, and a recognized leader in brain tumor imaging. Dr. Bernstein is participating as a co-investigator.

The trial is being sponsored by Imaging Biometrics, with supporting grants from the Musella Brain Tumor Foundation and the MCW Cancer Center. Based in Elm Grove, WI, Imaging Biometrics is a wholly owned subsidiary of IQ-AI Ltd.

With over a decade of experience in quantitative brain tumor imaging analysis, including analysis for several national multi-center trials, Imaging Biometrics will provide image analysis solutions for evaluating the response to GaM. “We are working with an excellent team of scientists and clinicians, and everyone is eager to move this study forward,” says Michael Schmainda, CEO of Imaging Biometrics.

The trial, being conducted at Froedtert & the Medical College of Wisconsin, is currently accepting participants and has an anticipated completion date of December 2025.

PRELIMINARY RESULTS OF A PHASE 1 TRIAL OF ORAL GALLIUM MALTOLATE IN RECURRENT GLIOBLASTOMA

Jennifer Connelly and others

Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v89, https://doi.org/10.1093/neuonc/noad179.0339

Published: 10 November 2023

Abstract

BACKGROUND

Glioblastoma (GBM) is an aggressive brain tumor with a dismal prognosis. New drugs that exploit previously underexplored cancer-related pathways are needed. We and others have shown that GBM stem cells require significantly greater amounts of iron than normal cells to drive critical iron-dependent processes that are altered in malignancy. We showed that oral gallium maltolate (GaM), an iron-targeting metal compound, has significant activity against GBM stem cells in vitro and shrinks GBM tumors and prolongs survival in a rat brain tumor model. GaM’s mechanisms include inhibition of cellular iron homeostasis, ribonucleotide reductase, and mitochondrial complex 1. Further study of GaM’s toxicity and benefit in patients with recurrent GBM is warranted.

METHODS

The Phase 1 trial design follows a 3 + 3 dose escalation scheme. Eligible patients will receive GaM at 3 dose levels: 500, 1,000, or 1,500 mg/day for a minimum of two 28-day cycles. Hepatic, renal, and hematologic functions, iron panel, and gallium levels are monitored every 2 weeks. Toxicity and tumor response are assessed by NCI CTCAE criteria and by RANO criteria, respectively. Patients with responding or stable disease may continue treatment with monitoring.

RESULTS

Ten patients have completed treatment at dose levels 1 and 2 and eight patients are evaluable. Four patients enrolled after first recurrence while the other four patients enrolled after their second, third (2 patients) and fourth recurrence. Median progression-free survival (PFS) on treatment was 118 days. Three patients experienced PFS >180 days and two of those patients remain on treatment. To-date, no dose-limiting toxicities (DLTs) at dose levels 1 and 2 have been encountered.

CONCLUSIONS

Oral GaM is well tolerated without significant DLTs to date. An additional 6 patients are presently enrolled at dose-level 3. Updated toxicity data and clinical outcomes of the study will be presented at the annual SNO meeting.

Wonder if the same seller for 6 x 75000 sells throughout the day?

Well less than 1 month ago we were 5p and now we are 40% lower yet we are arguably in a better position - a truly topsy turvy share that does the opposite of what you'd expect. (I'm aware of the shenanigans behind the fall).

Tyke you spoke too soon.

Anyone able to see L2?

17 trades but 2 x £10k in money so quite possible.

3.7 to sell small quantity and 3.73 to buy upto £5k worth.

Well I believe the last 5 reported sells are actually buys as buy price is below mid and I can't get a price to sell so I believe the mm's are not showing a true reflection for whatever reason.

No I bought 755,000 over 2 buys (over mid price so obvious buys) but there are some unknowns drifting through now?

Somethings amiss as I made 2 big buys around 12.30 and neither are showing on the trade page?

Tyke,

Without sounding like a lemming I too noticed this so just topped up with another 2.5k worth.

Wow..........thats a heavy loss.

I only have a tenth of yours but they were bought in the 3p days and it was my pension pot money thats sadly disappeared into the abyss.

Ironic really that when we dispensed with TB who was seen as the villian (encouraged by Cave) we seem to have been fleeced by a bigger set of scally's. One thing is for sure, Duffin will have a better retirement than me.

Duffin can't catch covid because he wears a mask (not the RMS ones btw) just one similar to Dick Turpin.